Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
Mitra AV., Bancroft EK., Barbachano Y., Page EC., Foster CS., Jameson C., Mitchell G., Lindeman GJ., Stapleton A., Suthers G., Evans DG., Cruger D., Blanco I., Mercer C., Kirk J., Maehle L., Hodgson S., Walker L., Izatt L., Douglas F., Tucker K., Dorkins H., Clowes V., Male A., Donaldson A., Brewer C., Doherty R., Bulman B., Osther PJ., Salinas M., Eccles D., Axcrona K., Jobson I., Newcombe B., Cybulski C., Rubinstein WS., Buys S., Townshend S., Friedman E., Domchek S., Ramon Y Cajal T., Spigelman A., Teo SH., Nicolai N., Aaronson N., Ardern-Jones A., Bangma C., Dearnaley D., Eyfjord J., Falconer A., Grönberg H., Hamdy F., Johannsson O., Khoo V., Kote-Jarai Z., Lilja H., Lubinski J., Melia J., Moynihan C., Peock S., Rennert G., Schröder F., Sibley P., Suri M., Wilson P., Bignon YJ., Strom S., Tischkowitz M., Liljegren A., Ilencikova D., Abele A., Kyriacou K., van Asperen C., Kiemeney L., IMPACT Study Collaborators None., Easton DF., Eeles RA.
OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS: Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS: In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS: The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.